The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

DOYLESTOWN, PA — Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...